Fibrinolytic response in malignancy

Páramo, José A.; Campbell, W. I.; Cuesta, B; Gómez, Clara; Aranda, A.; Rocha, Eduardo

doi:10.1016/0268-9499(87)90010-5

Cited by 11 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to findings in other malignant diseases [12,16,38,39], PA1 activity levels were unchanged in the two groups of patients studied. This lack of increase in PA1 was independent from the type as well as from the grade or stage of the carcinoma.…”

Section: Discussioncontrasting

confidence: 94%

“…PA1 has been described as an acute-phase protein in patients with septicaemia [26], extracorporeal circulation [25], the postoperative phase [22-241 and in patients with malignant tumours [16,39]. However, the malignant tumours in those studies were neither specified depending on the organ, tumour stage nor histological type [12,16,38,39]. Therefore, it is difficult to compare those data despite the fact that different laboratory standards and selection of subpopulations of patients might influence the results.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship between plasma levels of components of the fibrinolytic system and acute‐phase reactants in patients with uterine malignancies

Kirchheimer¹,

Koulbl

Tatra

et al. 1990

Eur J Clin Investigation

View full text Add to dashboard Cite

Plasma samples from 17 patients with endometrial cancer and from 52 patients with cervical carcinoma were determined with respect to their levels of components of the fibrinolytic system (tissue-type plasminogen activator antigen, urokinase-type plasminogen activator antigen, plasminogen activator inhibitor activity) and related to the observed alterations of three acute-phase reactants (C-reactive protein, coeruloplasmin, alpha-1-antitrypsin). As shown previously, uterine malignancies, especially at later stages, exhibited significant increases in plasma levels of urokinase-type plasminogen activator antigen as compared to an age-matched control group. In contrast, tissue-type plasminogen activator antigen and plasminogen activator inhibitor activity remained unchanged. Determination of the acute-phase reactants revealed significant changes in the case of C-reactive protein and coeruloplasmin in later tumour stages. However, the increase in urokinase-type plasminogen activator antigen did not correlate with the increase of either C-reactive protein or coeruloplasmin plasma level. These data indicate that the increase in plasma urokinase-type plasminogen activator antigen in patients with uterine malignancies does not follow the pattern of common acute-phase reactants, like C-reactive protein or coeruloplasmin.

show abstract

Section: Discussioncontrasting

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Relationship between plasma levels of components of the fibrinolytic system and acute‐phase reactants in patients with uterine malignancies

Kirchheimer¹,

Koulbl

Tatra

et al. 1990

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Although impairment of fibrinolysis is present in patients with cancer [21], any pos sible relationship between cancer and the observed changes in the fibrinolytic system has to be ruled out since no differences were found in patients with or without malig nancy.…”

Section: Discussionmentioning

confidence: 99%

Fibrinolytic Activity in Plasma after Gynecological and Urological Surgery

Aranda

Páramo

Rocha

1988

Pathophysiol Haemos Thromb

Self Cite

View full text Add to dashboard Cite

Fibrinolytic activity was studied in 51 patients subjected to major surgery (27 urological and 24 gynecological) without prophylaxis. Postoperative deep-vein thrombosis (DVT) was diagnosed by venography in 6 patients (11 %). Blood samples were obtained preoperatively and on days 1, 3 and 7 postoperatively. Reduced fibrinolytic activity, as determined by prolongation of euglobulin lysis time (ELT), decrease in plasminogen activators on fibrin plate and decrease in tissue-type plasminogen activator (t-PA) activity were present postoperatively. Moreover, a marked increase in short duration in fast-acting inhibitor (PA-inhibitor) levels was observed on postoperative day 1 (p < 0.001). Patients with DVT had higher fibrinogen degradation product (FDP) levels on postoperative days 3 and 7 (p < 0.02). Preoperative PA-inhibitor activity was higher (p < 0.02) in those patients who developed postoperative DVT. It is concluded that the decrease in t-PA and the increase in PA-inhibitor may contribute to the reduced postoperative fibrinolytic activity after major surgery. PA-inhibitor may represent a useful predictive marker of postoperative DVT.

show abstract

“…Los pacientes con cáncer presentan un desequilibrio entre el sistema de la coagulación y la fibrinolisis confiriéndoles un estado protrombótico [1][2][3][4][5][6][7][8][9][10] . Una de las proteínas hemostáticas que se encuentran elevadas en estos pacientes, es el factor von Willebrand (vWf) [11][12][13][14][15][16][17][18][19][20] .…”

Section: Introductionunclassified

El factor von Willebrand como intermediario entre la hemostasia y la angiogénesis de origen tumoral

Gil‐Bazo

Catalán²,

Páramo³

et al. 2017

revista-de-medicina

View full text Add to dashboard Cite

Los pacientes con cáncer presentan un desequilibrio entre el sistema de la coagulación y la fibrinolisis confiriéndoles un estado protrombótico. En él intervienen elementos sanguíneos moleculares que presentan niveles elevados en estos pacientes, como el factor von Willebrand (vWf). En la angiogénesis activada durante el crecimiento tumoral, el factor de crecimiento del endotelio vascular (VEGF) y el factor de crecimiento de fibroblastos (FGF-2), estimulan la proliferación del endotelio, productor junto con las plaquetas, del vWf, determinando niveles plasmáticos incrementados de éste, en pacientes oncológicos. Recientemente ha sido descrita la contribución del vWf a la adhesión entre células tumorales y plaquetas. El descubrimiento de integrinas de membrana de plaquetas, células endoteliales y tumorales y su mediación en la adhesión celular entre ellas han permitido demostrar agregación plaquetar y activación de la coagulación inducida por células tumorales unidas a plaquetas y la capacidad migratoria que adquieren las células neoplásicas en dicho proceso facilitando la generación de metástasis. Estudios clínicos demuestran elevación plasmática de vWf en enfermos con cáncer siendo mayores los niveles, a mayor estadio clínico-radiológico y en aquellos que presentan metástasis a distancia. Además, enfermos con niveles preoperatorios mayores de vWf, tienen menor supervivencia tras la resección quirúrgica tumoral. También se ha relacionado el mayor peso molecular de vWf en pacientes oncológicos con un déficit en la actividad proteasa de clivaje del vWf. Los resultados prometedores de la administración de antiagregantes/anticoagulantes a pacientes oncológicos abren la puerta de nuevas dianas terapéuticas en el cáncer.

show abstract

Fibrinolytic response in malignancy

Cited by 11 publications

References 23 publications

Relationship between plasma levels of components of the fibrinolytic system and acute‐phase reactants in patients with uterine malignancies

Relationship between plasma levels of components of the fibrinolytic system and acute‐phase reactants in patients with uterine malignancies

Fibrinolytic Activity in Plasma after Gynecological and Urological Surgery

El factor von Willebrand como intermediario entre la hemostasia y la angiogénesis de origen tumoral

Contact Info

Product

Resources

About